Date: 2018-04-23
Type of information: Nomination
Compound: member of the board of directors
Company: Lysogene (France)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 23, 2018, Lysogene appointed Dr. Peter Lichtlen to the Board of Directors, as a non-executive, independent member effective from April 1, 2018. Dr. Peter Lichtlen was Chief Medical Officer at Sucampo Pharmaceuticals until the company’s acquisition by Mallinckrodt Pharmaceuticals earlier this year and has 18 years of leadership experience in the field of biotechnology. Prior to joining Sucampo, Dr. Lichtlen was at ESBATech (acquired by Alcon/Novartis in 2009), which he joined in 2000. At ESBATech, Dr. Lichtlen served as Medical Director/Head Clinical Research and
Development and was a member of its senior management team, from 2004 to 2010.
- Dr. Lichtlen also co-founded Numab AG, a Swiss biotechnology company that develops antibody-based
therapeutics, where he remains a member of the Board of Directors and Chief Medical Officer. Dr. Lichtlen
also currently serves on the scientific advisory board of Apidel SA, a drug delivery company. Dr. Lichtlen is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of several patents. Dr. Lichtlen earned a Bachelor’s Degree in business administration, and doctorate degrees in medicine
and molecular biology at the University of Zurich.
Financial terms:
Latest news:
Is general: Yes
